Jubilant Pharmova approves ₹800 crore NCD issue
In short
Jubilant Pharmova approved an ₹800 crore NCD issue through private placement. The interest rate will be set through a bidding process.
This matters because it is a new borrowing plan for the pharmaceutical company. The reporting does not say when the issue will happen or what the money will be used for.
What the reporting says
Jubilant Pharmova approved an ₹800 crore non-convertible debenture issue through private placement, according to a market summary. The board also left the interest rate to be determined through the bidding process. The reporting does not state the timing of the issue, the use of proceeds, or which investors will buy the debt.
Why it matters
Jubilant Pharmova approved an ₹800 crore non-convertible debenture issue through private placement, with the interest rate to be discovered through bidding. The move points to debt fundraising by the pharmaceutical company, but the reporting does not state the timing, tenor, or end use of the proceeds. It also does not say how investors responded or whether the issue has been placed.